| dc.creator |
Yildirim, Seda |
|
| dc.creator |
Aydin, Memduha |
|
| dc.creator |
Ilhan, Bilge Cetin |
|
| dc.creator |
Eren, İbrahim |
|
| dc.creator |
Calisir, Saliha |
|
| dc.date |
2016-02-01T01:00:00Z |
|
| dc.date.accessioned |
2025-02-25T10:34:11Z |
|
| dc.date.available |
2025-02-25T10:34:11Z |
|
| dc.identifier |
90d9e967-150f-40f3-afc5-bc2b7efd94a5 |
|
| dc.identifier |
10.1177/2045125315624063 |
|
| dc.identifier |
https://avesis.sdu.edu.tr/publication/details/90d9e967-150f-40f3-afc5-bc2b7efd94a5/oai |
|
| dc.identifier.uri |
http://acikerisim.sdu.edu.tr/xmlui/handle/123456789/100561 |
|
| dc.description |
Objective: Clozapine is a second-generation antipsychotic used for treatment-resistant schizophrenia. Despite its effectiveness, clozapine is largely underused due to serious side effects such as leukopenia or neutropenia. We aimed to review whether to continue, discontinue or rechallenge clozapine treatment after such haematological side effects. |
|
| dc.language |
eng |
|
| dc.rights |
info:eu-repo/semantics/closedAccess |
|
| dc.title |
Continuing clozapine treatment with lithium in schizophrenic patients with neutropenia or leukopenia: brief review of literature with case reports |
|
| dc.type |
info:eu-repo/semantics/article |
|